Managed Healthcare Executive12h
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...
Pharmaceutical Technology on MSN17h
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
The Pharma Letter18h
Trimtech raises $31 million seed funding for targeted protein degradation pipeline in neurodegeneration
UK-based Trimtech Therapeutics, a biotech harnessing targeted protein degradation (TPD) for neurodegenerative diseases, has ...
PMLive22h
BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use
BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...
The Pharma Letter23h
Russian trade groups call on govt to postpone discriminatory procurement rules
Leading pharmaceutical associations in Russia have called on the government to postpone the introduction of new procurement ...